Dengue drug discovery

Topics in Medicinal Chemistry

Volumn 7, Issue , 2011, Pages 243-276

  Shi, Pei Yong ^a   Yin, Zheng ^b   Nilar, Shahul ^a   Keller, Thomas H ^c  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NANKAI UNIVERSITY   (China)

^c Agency for Science   (Singapore)

Author keywords

Dengue; E protein; Flavivirus; Glucosidase; NS3 protease; NS5 polymerase

Indexed keywords

1 DEOXYNOJIRIMYCIN; 4' AZIDOCYTIDINE; 9 DEAZA 2'C ETHYNYL ADENOSINE; ANTIVIRUS AGENT; BALAPIRAVIR; CASTANOSPERMINE; CASTANOSPERMINE 6 BUTYRATE; E PROTEIN; ENFUVIRTIDE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 2A; NONSTRUCTURAL PROTEIN 2B; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA; QUINAZOLINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DENGUE; DENGUE VIRUS; DRUG INHIBITION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; RNA TRANSLATION; SINGLE DRUG DOSE; VIRUS GENOME; VIRUS REPLICATION;

EID: 80054899372     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2011_16     Document Type: Article

References (109)

1. Stevens AJ, Gahan ME et al (2009) The medicinal chemistry of dengue. J Med Chem 52:7911-7926
2. Noble CG, Chen YL et al (2010) Strategies for the development of dengue virus inhibitors. Antivir Res 85:450-462
3. Gubler D, Kuno G et al (2007) Flaviviruses. In: Knipe DM, Howley PM (eds) Fields virology, vol 1, 5th edn. Lippincott William & Wilkins, Philadelphia
4. Wills B (2008) Management of dengue. In: Halstead SB (ed) Dengue. Imperial College Press, London
5. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-67 (Pubitemid 137639381)
6. Esté JA, Telenti A (2007) HIV entry inhibitors. Lancet 370:81-88 (Pubitemid 47018315)
7. Keller TH, Chen YL et al (2006) Finding new medicines for flaviviral diseases. Novartis Found Symp 277:102-114
8. Zhang W, Chipman PR et al (2003) Visualization of membrane protein domains by cryoelectron microscopy of dengue virus. Nat Struct Biol 10:907-12 (Pubitemid 37386099)
9. Kummerer BM, Rice CM (2002) Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J Virol 76:4773-4784 (Pubitemid 34441683)
10. Liu WJ, Chen HB et al (2003) Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J Virol 77:7804-13 (Pubitemid 36792777)
11. Liu W, Wang X et al (2005) Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J Virol 79:1934-42 (Pubitemid 40459140)
12. Munoz-Jordan JL, Sanchez-Burgos GG et al (2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci USA 100:14333-8 (Pubitemid 37499237)
13. Falgout B,Miller RHet al (1993)Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J Virol 67:2034-42 (Pubitemid 23088377)
14. Wengler G, Wengler G (1991) The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 184:707-15
15. Wengler G, Wengler G (1993) The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273
16. Ackermann M, Padmanabhan R (2001) De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem 276:39926-39937
17. Egloff MP, Benarroch D et al (2002) An RNA cap (nucleoside-2'-O-)- methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J 21:2757-68 (Pubitemid 34619391)
18. Tan BH, Fu J (1996) Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216:317-25 (Pubitemid 26083377)
19. Lindenbach B, Rice C (1997) trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. J Virol 71:9608-9617 (Pubitemid 27492408)
20. Miller S, Sparacio S (2006) Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J Biol Chem 281:8854-63 (Pubitemid 43847992)
21. Miller S, Kastner S et al (2007) The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. J Biol Chem 282:8873-82 (Pubitemid 47093477)
22. Blackwell JL, Brinton MA (1997) Translation elongation factor-1 alpha interacts with the 3' stem-loop region of West Nile virus genomic RNA. J Virol 71:6433-44 (Pubitemid 27355297)
23. Davis W, Blackwell J et al (2007) Interaction between the cellular protein eEF1A and the 3' terminal stem loop of the West Nile virus genomic RNA facilitates viral RNA minus strand synthesis. J Virol 81:10172-10187 (Pubitemid 350067720)
24. Ma L, Jones CT (2004) Solution structure of dengue virus capsid protein reveals another fold. Proc Natl Acad Sci USA 101:3414-9 (Pubitemid 38338209)
25. Li L, Lok SM et al (2008) The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830-4 (Pubitemid 351451591)
26. Modis Y, Ogata S et al (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100:6986-6991 (Pubitemid 36706380)
27. Erbel P, Schiering N et al (2006) Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol 13:372-273
28. Luo D, Xu T et al (2008) Crystal structure of the NS3 protease-helicase from dengue virus. J Virol 82:173-183 (Pubitemid 350309134)
29. Yap TL, Xu T et al (2007) Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. J Virol 81:4753-4765 (Pubitemid 46668672)
30. van der Schaar HM, Rust MJ et al (2008) Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog 4:e1000244
31. Navarro-Sanchez E, Altmeyer R et al (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquitocell- derived dengue viruses. EMBO Rep 4:723-728 (Pubitemid 36974759)
32. Thepparit C, Smith DR (2004) Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor. J Virol 78:12647-12656 (Pubitemid 39458782)
33. Miller JL, deWet BJM et al (2008) The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 4:e17
34. Jindadamrongwech S, Thepparit S (2004) Identification of GRP 78 (BiP) as a liver cell expressed receptor element for dengue virus serotype 2. Arch Virol 149:915-927 (Pubitemid 38641472)
35. Marks RM, Lu H et al (2001) Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J Med Chem 44:2178-2187 (Pubitemid 32861777)
36. Ono L, Wollinger W (2003) In vitro and in vivo antiviral properties of sulfated galactomannans against yellow fever virus (BeH111 strain) and dengue 1 virus (Hawaii strain). Antivir Res 60:201-208 (Pubitemid 37456868)
37. Talarico LB, Damonte EB (2007) Interference in dengue virus adsorption and uncoating by carrageenans. Virology 363:473-485 (Pubitemid 46766683)
38. Modis Y, Ogata S et al (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319 (Pubitemid 38133652)
39. Hrobowski YM, Garrey RF et al (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2:49-59
40. Li Z, Khaliq M et al (2008) Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem 51:4660-4670
41. Zhou Z, Kalique M et al (2008) Antiviral compounds discovered by virtual screening of small molecule libraries against dengue virus E protein. ACS Chem Biol 3:765-775
42. Kampmann T, Yennamalli R et al (2009) In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antivir Res 84:234-241
43. Wang QY, Patel SJ et al (2009) A small-molecule dengue virus inhibitor. Antimicrob Agents Chemother 53:1823-1831
44. Xu T, Sampath A et al (2005) Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A ̊ . J Virol 79:10278-10288 (Pubitemid 41098569)
45. Assenberg R, Mastrangelo E et al (2009) Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. J Virol 83:12895-12906
46. Luo D, Wei N et al (2010) Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J Biol Chem 285:18817-18827
47. Hsu JT, Wang HC (2006) Antiviral drug discovery targeting to viral proteases. Curr Pharm Des 12:1301-1314 (Pubitemid 44082114)
48. Menendez-Arias L (2010) Molecular basis of human immunodeficiency virus drug resistance: an update. Antivir Res 85:210-231
49. Thompson AJV, McHutchison JG (2009) Investigational agents for chronic hepatitis C. Aliment Pharmacol Ther 29:689-705
50. Bazan JF, Fletterick RJ et al (1989) Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171:637-639 (Pubitemid 19210412)
51. Falgout B, Pethel M et al (1991) Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 65:2467-2475
52. Murthy HMK, Clum S et al (1999) Dengue virus NS3 serine protease. J Biol Chem 274:5573-5580
53. Chambers TJ, Weir RC et al (1990) Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Nat Acad Sci USA 87:8898-8902 (Pubitemid 120007616)
54. Preugschat F, Yao CW et al (1990) In vitro processing of dengue virus type 2 nonstructural proteins NS2A, NS2B and NS3. J Virol 64:4364-4374 (Pubitemid 20279847)
55. Chanparpaph S, Saparpakorn P et al (2005) Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun 330:1237-1246
56. Li J, Lim SP et al (2005) Functional profiling of recombinant of NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 280:48535-49542
57. Yin Z, Patel SJ et al (2006) Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg Med Chem Lett 16:36-39 (Pubitemid 41625636)
58. Yin Z, Pate SJ et al (2006) Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett 16:40-43 (Pubitemid 41625637)
59. Aleshin A, Shiryaev S et al (2007) Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci 16:795-806 (Pubitemid 46683185)
60. Ganesh VK, Muller N et al (2005) Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Biorg Med Chem 13:257-264 (Pubitemid 39575709)
61. Bodenreider C, Beer D et al (2009) A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal Biochem 395:195-204
62. Mueller NH, Pattabiraman N et al (2008) Identification and biochemical characterization of small-molecule inhibitors of West Nile virus serine protease by a high-throughput screen. Antimicrob Agents Chemother 52:3385-3393
63. Kiat TS, Pippen R et al (2006) Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Int J Biol Sci 16:3337-3340
64. Tomlinson SM, Malmstrom RD et al (2009) Structure-based discovery of dengue virus protease inhibitors. Antivir Res 82:110-114
65. Robin G, Chappel K et al (2009) Structure of west Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol 385:1568-1577
66. Chandramouli S, Joseph J et al (2010) Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol 84:3059-3067
67. Knox JE, Ma NL et al (2006) Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors. J Med Chem 49:6585-6590 (Pubitemid 44657452)
68. Keller TH, Pichota A et al (2006) A practical view of druggability. Curr Opin Chem Biol 10:357-361
69. Liu Y, JiangWWet al (2006) Mechanistic study of HCV polymerase inhibitors at individual steps of the polymerization reaction. Biochemistry 45:11312-11323 (Pubitemid 44453979)
70. Malet H, Massé N et al (2008) The flavivirus polymerase as a target for drug discovery. Antivir Res 80:23-35
71. Steitz TA, Smerdon SJ et al (1994) A unified polymerase mechanism for nonhomologous DNA and RNA polymerases. Science 266:2022-2025
72. Li H, Shi ST (2010) Non-nucleoside inhibitors of hepatitis C virus polymerase: current progress and future challenges. Future Med Chem 2:121-141
73. Perrone P, Daveria F et al (2007) First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J Med Chem 50:5463-5470 (Pubitemid 350057856)
74. Migliaccio G, Tomassini JE et al (2003) Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278:49164-49170
75. Eldrup AB, Prhavc M et al (2004) Structure-activity relationship of heterobase-modified 20-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem 47:5284-5297 (Pubitemid 39314927)
76. Chen YL, Yin Z et al (2010) Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob Agents Chemother 54:2932-2939
77. Pastor-Anglada M, Cano-Soldado P et al (2005) Cell entry and export of nucleoside analogues. Virus Res 107:151-164 (Pubitemid 40093088)
78. Butora G, Olsen DB et al (2007) Synthesis and HCV inhibitory properties of 9-deaza- and 7,9-dideaza-7-oxa-20-C-methyladenosine. Bioorg Med Chem 15:5219-5229 (Pubitemid 46880374)
79. Carroll SS, Ludmerer S et al (2009) Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 53:926-934
80. Yin Z, Chen YL et al (2009) An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 106:20435-20439
81. Yin Z, Chen YL et al (2009) N-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase. J Med Chem 52:7934-7937
82. Smith DB, Martin JA et al (2007) Design, synthesis, and antiviral properties of 40-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479. Bioorg Med Chem Lett 17:2570-2576 (Pubitemid 46509839)
83. Pockros PJ, Nelson D et al (2008) R1626 Plus peginterferon alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 48:395-397
84. LiH, Tatlock J et al (2009) Discovery of (R)-6-cyclopentyl-6-(2-(2,6- diethylpyridin-4-yl)ethyl)- 3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- yl)methyl)-4-hydroxy-5,6-dihydropyran-2- one(PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 52:1255-1258
85. Niyomrattanakit P, Chen YL et al (2010) Inhibition of dengue virus polymerase by blocking of the RNA tunnel. J Virol 84:5678-5686
86. Ray D, Shah A et al (2006) West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. J Virol 80:8362-70 (Pubitemid 44384849)
87. Chung KY, Dong H et al (2010) Higher catalytic efficiency of N-7-methylation is responsible for processive N-7 and 2'-O methyltransferase activity in dengue virus. Virology 402:52-60
88. Dong H, Chang D et al (2010) Biochemical and genetic characterization of dengue virus methyltransferase. Virology 405:568-578
89. Dong H, Ray D et al (2007) Distinct RNA elements confer specificity to flavivirus RNA cap methylation events. J Virol 81:4412-4421 (Pubitemid 46668638)
90. Dong H, Zhang B et al (2008) Flavivirus methyltransferase: a novel antiviral target. Antivir Res 80:1-10
91. Zhou Y, Ray D et al (2007) Structure and function of flavivirus NS5 methyltransferase. J Virol 81:3891-3903 (Pubitemid 46586885)
92. Copeland RA, Solomon ME et al (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8:724-32
93. Dong H, Liu L et al (2010) Structural and functional analyses of a conserved hydrophobic pocket of flavivirus methyltransferase. J Biol Chem 285:32586-32595
94. Jacoby GS (1995) Glycosylation inhibitors in biology and medicine. Curr Opin Struct Biol 5:605-611
95. Elbein AD (1991) Glycosidase inhibitors: inhibitors of N-linked oligosaccharide processing. FASEB J 5:3055-3063 (Pubitemid 21892865)
96. Pan YT, Hori H et al (1983) Castanospermine inhibits the processing of the oligosaccharide portion of the influenza hemagglutinin. Biochemistry 22:3975-3983
97. Block TM, Lu X et al (1998) Treatment of chronic hepadnavirus infection in woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 4:610-614 (Pubitemid 28237362)
98. Courageot MP, Frenkiel MP (2000) a-Glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J Virol 74:564-572
99. Schul W, Wei L et al (2007) A dengue fever viremia model in mice show reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195:665-674
100. Gloster TM, Madsen R et al (2006) Dissection of conformationally restricted inhibitors binding to a b-glucosidase. Chembiochem 7:738-742 (Pubitemid 43764180)
101. Tan A, van den Broek L et al (1991) Chemical modifications of the glucosidase inhibitor 1-deoxynojirimycin. J Biol Chem 22:14504-14510 (Pubitemid 21907532)
102. Mellor HR, Nolan J (2002) Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins. Biochem J 366:225-233 (Pubitemid 34971822)
103. Wu SF, Lee CJ et al (2002) Antiviral effects of an iminosugar derivative on flavivirus infections. J Virol 76:3595-3604
104. Gu B, Mason P (2007) Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother 18:49-59 (Pubitemid 46426937)
105. Chang J, Wang L (2009) Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Anitmicrob Agents Chemother 53:1501-1508
106. Whitby K, Pierson TC et al (2005) Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol 79:8698-8706 (Pubitemid 40934780)
107. Sorbera LA, Castaner J et al (2005) Celgosivir. Drug Future 30:545-552
108. Durantel D (2009) Celgosivir, an a-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig D 10:860-870
109. Tassaneetrithep B, Burgess TH et al (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 7:823-829 (Pubitemid 36437860)